A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs RO 7082859 (Primary) ; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisone; Prednisone; Rituximab; Tocilizumab; Vincristine
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 17 Oct 2019 Status changed from active, no longer recruiting to recruiting.
- 11 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2019 Planned End Date changed from 17 Jun 2023 to 16 Dec 2023.